Compare Celsius Holdings, Inc. (CELH) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Celsius Holdings, Inc. vs Novo Nordisk A/S — how do they compare? Celsius Holdings, Inc. trades at $27.99 (market cap $7.11B), while Novo Nordisk A/S trades at $45.88 (market cap $207.85B). The key difference: Novo Nordisk A/S is far larger — about 29.2× Celsius Holdings, Inc.'s market cap, and Novo Nordisk A/S pays a 3.81% dividend while Celsius Holdings, Inc. pays none. Which is the better fit depends on your goals.
| CELH | NVO | |
|---|---|---|
Market Cap | $7.11B | $207.85B |
Sector | Consumer Staples | Health |
52-Week High | $64.86 | $63.98 |
52-Week Low | $23.77 | $35.29 |
Enterprise Value | $8.90B | $222.55B |
Dividend Yield | — | 3.81% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Celsius Holdings, Inc.
Celsius Holdings Inc engages in the development, marketing, sale, and distribution of functional calorie-burning beverages. It offers flavors including cola, orange, wild berry and lemon iced tea and non-carbonated flavors such as Raspberry Acai Green Tea and Peach Mango Green Tea under the Celsius brand name. The company distributes its products through direct-store-delivery distributors, as well as directly to retailers across various retail segments, including supermarkets, convenience stores, drug stores, nutritional stores, mass merchants, health clubs, spas, gyms, military, and e-commerce websites.
Read more on CELH →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
